ReviewThe Journal of infectious diseases2015
Raising expectations for subunit vaccine.
Review in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Recent advances on coxsackievirus A6 vaccine research.Frontiers in immunology · 2025Pooled it
- Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials.The Journal of infectious diseases · 2018Trial
- Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.Journal of the National Cancer Institute · 2018Trial
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.The Lancet. Oncology · 2015Trial
- Biodegradable Polymers for Application as Robust Immunomodulatory Biomaterial Carrier Systems.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Development of a single-dose Q fever vaccine with an injectable nanoparticle-loaded hydrogel: effect of sustained co-delivery of antigen and adjuvant.Drug delivery · 2025Article
- Human anthrax vaccines: Current status and future prospects.Human vaccines & immunotherapeutics · 2025Review
- Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.Infectious agents and cancer · 2025Review
- Antivirotics based on defective interfering particles: emerging concepts and challenges.Frontiers in cellular and infection microbiology · 2025Review
- The community nurse's role on the promotion of papillomavirus vaccination among young students: A study protocol.Human vaccines & immunotherapeutics · 2024Article
- Vaccines targetingHuman vaccines & immunotherapeutics · 2024Article
- Tuberculosis Vaccines and T Cell Immune Memory.Vaccines · 2024Review
- A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease.Cell reports. Medicine · 2024Article
- Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses.Viruses · 2024Review
- Review
- COVID-19 spike polypeptide vaccine reduces the pathogenesis and viral infection in a mouse model of SARS-CoV-2.Frontiers in immunology · 2023Article
- Review
- Article
- Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform.Nano research · 2022Review
- Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.Nature communications · 2021Article
Corrections and comments
- Commented on by
- Commented on byReply to Nalin.2015
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Multidose regimens are recommended for all prophylactic subunit vaccines. Recent findings from clinical trials of an human papillomavirus virus-like particle vaccine suggest that it may be possible to develop effective single-dose subunit vaccines. The broad implications of these findings are discussed, and the importance of antigen structure and adjuvant in achieving this goal is considered. In conclusion, we argue for the inclusion of single-dose arms in future trials of vaccines, especially if they are based on induction of antibodies by virus-like displayed antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.